Trial 0C-16-3


An Open-Label, Non-Randomized, Multicenter Phase I Study to Determine the Maximum Tolerated or Recommended Phase II Dose of Oral Mutant IDH1 Inhibitor BAY 1436032 and to Characterize its Safety, Tolerability, Pharmacokinetics and Preliminary Pharmacodynamic and Anti-Tumor Activity in Patients with IDH1-R132X-Mutant Advanced Solid Tumors

Type: Treatment
Phase: Phase I
Status: Not Open (Closed)
Treatments: Chemotherapy: Systemic
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Heinz Josef Lenz, M.D.
Other Trial Staff:  Xiomara Menendez, Coordinator, Jubilee Acap, Coordinator, Arthur Alvarez, D.M., Khatchik Karakozian, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.